PL1842920T3 - Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K - Google Patents

Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K

Info

Publication number: PL1842920T3
Authority: PL; Poland
Prior art keywords: vitamin; dependent protein; reductase; productivity; improve
Prior art date: 2003-09-23

Application number

PL07109353T

Other languages

English (en)

Other versions

PL1842920T5 (pl

Inventor

Darrel Stafford

Tao Li

Original Assignee

Univ North Carolina Chapel Hill

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-23

Filing date

2004-09-23

Publication date

2010-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34393028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1842920(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-09-23 Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill

2010-06-30 Publication of PL1842920T3 publication Critical patent/PL1842920T3/pl

2018-04-30 Publication of PL1842920T5 publication Critical patent/PL1842920T5/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

Landscapes

Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Virology (AREA)
Plant Pathology (AREA)
Pathology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

PL07109353T 2003-09-23 2004-09-23 Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K PL1842920T5 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US50552703P	2003-09-23	2003-09-23
EP07109353.8A EP1842920B2 (en)	2003-09-23	2004-09-23	Cells coexpressing vitamin K reductase and vitamin K dependent protein and use thereof to improve the productivity of said vitamin K dependent protein
EP04789039.7A EP1670947B1 (en)	2003-09-23	2004-09-23	Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage

Publications (2)

Publication Number	Publication Date
PL1842920T3 true PL1842920T3 (pl)	2010-06-30
PL1842920T5 PL1842920T5 (pl)	2018-04-30

Family

ID=34393028

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07109353T PL1842920T5 (pl)	2003-09-23	2004-09-23	Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K

Country Status (12)

Country	Link
US (6)	US7687233B2 (pl)
EP (4)	EP2336360A1 (pl)
JP (4)	JP2007506433A (pl)
AT (1)	ATE455174T1 (pl)
AU (2)	AU2004275828B2 (pl)
CA (1)	CA2539434C (pl)
DE (1)	DE602004025157D1 (pl)
DK (2)	DK2380985T3 (pl)
ES (2)	ES2453895T3 (pl)
PL (1)	PL1842920T5 (pl)
PT (1)	PT2380985E (pl)
WO (1)	WO2005030039A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2336360A1 (en)	2003-09-23	2011-06-22	University Of North Carolina At Chapel Hill	Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
EP2272951B1 (en)	2003-10-14	2014-07-23	Baxter International Inc.	Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
GB0324044D0 (en)	2003-10-14	2003-11-19	Astrazeneca Ab	Protein
WO2006012902A2 (en) *	2004-08-02	2006-02-09	Novozymes A/S	Creation of diversity in polypeptides
US7445896B2 (en)	2004-10-18	2008-11-04	University Of Washington	Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
WO2006044686A2 (en) *	2004-10-18	2006-04-27	University Of Washington	Methods and compositions for predicting drug responses
PL1831402T3 (pl) *	2004-12-21	2010-12-31	Academia Sinica	Genetyczne warianty VKORC1 przewidujące wrażliwość na warfarynę
MX349285B (es) *	2005-02-28	2017-07-20	Baxalta Inc	Co-expresion recombinante de reductasa de epoxido de vitamina k subunidad 1 para mejorar la expresion de proteina dependiente de vitamina k.
US20090325226A1 (en) *	2005-03-15	2009-12-31	Stafford Darrel W	Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
MX2007012704A (es) *	2005-04-13	2008-01-14	Astrazeneca Ab	Celula huesped que comprende vector para la produccion de proteinas que requieren carboxilacion-gamma.
US8500720B2 (en) *	2005-05-09	2013-08-06	Medtronic, Inc	Method and apparatus for treatment of cardiac disorders
PL1969127T5 (pl) *	2005-12-21	2018-02-28	Cnj Holdings, Inc	Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
US20070298426A1 (en) *	2006-06-02	2007-12-27	Academia Sinica	Warfarin dosage prediction
US8206967B2 (en)	2007-07-06	2012-06-26	Medimmune Limited	Method for production of recombinant human thrombin
ES2466340T3 (es)	2008-04-24	2014-06-10	Cantab Biopharmaceuticals Patents Limited	Conjugados de Factor IX con semividas extendidas
WO2010045381A2 (en) *	2008-10-15	2010-04-22	President And Fellows Of Harvard College	Antimicrobial agents that target bacterial vkor
DK2451963T3 (da)	2009-07-10	2014-08-04	Csl Ltd	Fremgangsmåde til forøgelse afvitamin-k-afhængige proteiners exprimerings-ydelse
EP2655607A4 (en)	2010-12-21	2014-05-14	Univ North Carolina	METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
JP2012139232A (ja) *	2012-03-15	2012-07-26	Univ Of North Carolina At Chapel Hill	活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
JP2014221048A (ja) *	2014-06-16	2014-11-27	ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル	活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
BR102015012334A2 (pt)	2015-05-27	2016-11-29	Fundação Hemoct De Ribeirão Preto Fundherp	processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
EP3551034A1 (en)	2016-12-07	2019-10-16	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
AU2019383976B2 (en)	2018-11-19	2025-07-03	Bt Bidco, Inc.	Methods and devices for treating a disease with biotherapeutics
US11707610B2 (en)	2019-12-13	2023-07-25	Biora Therapeutics, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA811368B (en)	1980-03-24	1982-04-28	Genentech Inc	Bacterial polypedtide expression employing tryptophan promoter-operator
GB8308235D0 (en) *	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0127839B1 (en)	1983-05-27	1992-07-15	THE TEXAS A&M UNIVERSITY SYSTEM	Method for producing a recombinant baculovirus expression vector
US4736866B1 (en) *	1984-06-22	1988-04-12		Transgenic non-human mammals
EP0218713B1 (en)	1985-04-22	1992-03-25	Genetics Institute, Inc.	High yield production of active factor ix
DE3785186T2 (de)	1986-09-02	1993-07-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
AU8339187A (en)	1986-11-17	1988-06-16	New England Medical Center Hospitals, Inc., The	Enhancing gamma-carboxylation of recombinant vitamin k-dependent proteins
JPH03501921A (ja)	1987-05-18	1991-05-09	インテグレイテッド・ジェネティクス・インク	改良タンパク質分子、並びにその製造及び活性化方法
JP2919890B2 (ja)	1988-11-11	1999-07-19	メディカルリサーチカウンスル	単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
WO1991001372A1 (en)	1989-07-17	1991-02-07	New England Medical Center Hospitals, Inc.	VITAMIN K-DEPENDENT η-CARBOXYLASE
CA2087970A1 (en) *	1990-07-23	1992-01-24	Kathleen L. Berkner	Gamma-carboxylase and methods of use
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5169784A (en)	1990-09-17	1992-12-08	The Texas A & M University System	Baculovirus dual promoter expression vector
JP4236698B2 (ja)	1990-11-26	2009-03-11	ジェネティックスインスティチュート，リミテッドライアビリティカンパニー	宿主細胞でのｐａｃｅの発現およびその使用法
US5965789A (en)	1991-01-11	1999-10-12	American Red Cross	Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en)	1991-05-08	1993-12-07	The University Of North Carolina At Chapel Hill	Vitamin K-dependent carboxylase
JP3540315B2 (ja)	1991-09-23	2004-07-07	メディカルリサーチカウンシル	キメラ抗体の製造−組合せアプローチ
US5698765A (en) *	1991-12-02	1997-12-16	The Ontario Cancer Institute	Mouse having a disrupted CD4 gene
WO1993018144A1 (en) *	1992-03-05	1993-09-16	The Trustees Of Columbia University Of The City Of New York	Recombination activating gene deficient animal
US5625122A (en) *	1992-04-24	1997-04-29	The Ontario Cancer Institute	Mouse having a disrupted lck gene
JP3741447B2 (ja) *	1992-10-23	2006-02-01	中外製薬株式会社	エンドセリン−１遺伝子の機能が欠損したマウス
US5547835A (en) *	1993-01-07	1996-08-20	Sequenom, Inc.	DNA sequencing by mass spectrometry
US5605798A (en) *	1993-01-07	1997-02-25	Sequenom, Inc.	DNA diagnostic based on mass spectrometry
WO1995034679A2 (en)	1994-06-16	1995-12-21	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Defects in drug metabolism
ZA965853B (en) *	1995-07-13	1998-01-12	Du Pont Merck Pharma	Asymmetric synthesis of r and s warfarin and its analogs.
DE19625049A1 (de)	1996-06-22	1998-01-02	Inst Pflanzengenetik & Kultur	Transgenes, nicht-menschliches Säugetier, das ein zusätzliches DNA-Reparaturgen enthält
US5888809A (en)	1997-05-01	1999-03-30	Icos Corporation	Hamster EF-1α transcriptional regulatory DNA
WO1999003496A1 (en)	1997-07-21	1999-01-28	The University Of North Carolina At Chapel Hill	Factor ix antihemophilic factor with increased clotting activity
EP1042473A1 (en)	1997-12-24	2000-10-11	Immunex Corporation	V201 dna and polypeptides
US5896337A (en)	1998-02-23	1999-04-20	Micron Technology, Inc.	Circuits and methods for multi-level data through a single input/ouput pin
JP2002532056A (ja) *	1998-07-10	2002-10-02	インサイト・ファーマスーティカルズ・インコーポレイテッド	ヒト輸送タンパク質相同体
WO2000030152A1 (en) *	1998-11-18	2000-05-25	Koninklijke Philips Electronics N.V.	Luminescent material
AU3629800A (en)	1999-03-16	2000-10-04	Children's Hospital Of Philadelphia, The	Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6453244B1 (en) *	2000-02-10	2002-09-17	Stanford University	Detection of polymorphisms by denaturing high-performance liquid chromatography
US6492115B1 (en) *	2000-06-02	2002-12-10	Dna Sciences Laboratories, Inc.	Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
EP1325113B1 (en)	2000-10-02	2010-04-21	Novo Nordisk Health Care AG	Factor vii glycoforms
AU2002226028A1 (en)	2000-11-14	2002-05-27	Board Of Regents, Unversity Of Texas Systems	Mutant human factor ix with an increased resistance to inhibition by heparin
CA2441417A1 (en) *	2001-03-21	2002-11-14	Human Genome Sciences, Inc.	Human secreted proteins
EP2336360A1 (en)	2003-09-23	2011-06-22	University Of North Carolina At Chapel Hill	Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
EP2272951B1 (en)	2003-10-14	2014-07-23	Baxter International Inc.	Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
GB0324044D0 (en)	2003-10-14	2003-11-19	Astrazeneca Ab	Protein
US7445896B2 (en) *	2004-10-18	2008-11-04	University Of Washington	Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
WO2006044686A2 (en)	2004-10-18	2006-04-27	University Of Washington	Methods and compositions for predicting drug responses
PL1831402T3 (pl) *	2004-12-21	2010-12-31	Academia Sinica	Genetyczne warianty VKORC1 przewidujące wrażliwość na warfarynę
US20090100533A1 (en)	2004-12-21	2009-04-16	Novo Nordisk Health Care Ag	Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host sytems
MX349285B (es)	2005-02-28	2017-07-20	Baxalta Inc	Co-expresion recombinante de reductasa de epoxido de vitamina k subunidad 1 para mejorar la expresion de proteina dependiente de vitamina k.
US20090325226A1 (en)	2005-03-15	2009-12-31	Stafford Darrel W	Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
MX2007012704A (es)	2005-04-13	2008-01-14	Astrazeneca Ab	Celula huesped que comprende vector para la produccion de proteinas que requieren carboxilacion-gamma.
EP1963506B1 (en)	2005-12-02	2010-10-27	Wake Forest University Health Sciences	Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
PL1969127T5 (pl)	2005-12-21	2018-02-28	Cnj Holdings, Inc	Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
US20070298426A1 (en)	2006-06-02	2007-12-27	Academia Sinica	Warfarin dosage prediction
JP2009005240A (ja) *	2007-06-25	2009-01-08	Nec Tokin Corp	無線ネットワークシステムおよび無線ネットワーク通信方法

2004
- 2004-09-23 EP EP10178665A patent/EP2336360A1/en not_active Withdrawn
- 2004-09-23 ES ES11156979.4T patent/ES2453895T3/es not_active Expired - Lifetime
- 2004-09-23 US US10/573,131 patent/US7687233B2/en not_active Expired - Fee Related
- 2004-09-23 AU AU2004275828A patent/AU2004275828B2/en not_active Expired
- 2004-09-23 WO PCT/US2004/031481 patent/WO2005030039A2/en not_active Ceased
- 2004-09-23 AT AT07109353T patent/ATE455174T1/de not_active IP Right Cessation
- 2004-09-23 EP EP07109353.8A patent/EP1842920B2/en not_active Expired - Lifetime
- 2004-09-23 ES ES07109353.8T patent/ES2339710T5/es not_active Expired - Lifetime
- 2004-09-23 DK DK11156979.4T patent/DK2380985T3/en active
- 2004-09-23 EP EP04789039.7A patent/EP1670947B1/en not_active Expired - Lifetime
- 2004-09-23 DK DK07109353.8T patent/DK1842920T4/da active
- 2004-09-23 PL PL07109353T patent/PL1842920T5/pl unknown
- 2004-09-23 PT PT111569794T patent/PT2380985E/pt unknown
- 2004-09-23 CA CA2539434A patent/CA2539434C/en not_active Expired - Lifetime
- 2004-09-23 JP JP2006528251A patent/JP2007506433A/ja not_active Withdrawn
- 2004-09-23 DE DE602004025157T patent/DE602004025157D1/de not_active Expired - Lifetime
- 2004-09-23 EP EP11156979.4A patent/EP2380985B1/en not_active Expired - Lifetime
2006
- 2006-09-06 US US11/516,229 patent/US7524665B2/en not_active Expired - Lifetime
2007
- 2007-01-30 US US11/699,930 patent/US7482141B2/en not_active Expired - Lifetime
- 2007-10-26 US US11/924,707 patent/US8097410B2/en not_active Expired - Fee Related
2009
- 2009-01-28 US US12/361,053 patent/US7858318B2/en not_active Expired - Fee Related
2010
- 2010-07-02 JP JP2010151738A patent/JP5094920B2/ja not_active Expired - Fee Related
- 2010-07-26 AU AU2010203318A patent/AU2010203318B2/en not_active Ceased
- 2010-12-17 US US12/971,574 patent/US8426128B2/en not_active Expired - Fee Related
2012
- 2012-03-12 JP JP2012054537A patent/JP5840539B2/ja not_active Expired - Lifetime
2015
- 2015-05-07 JP JP2015094928A patent/JP2015180205A/ja active Pending

Also Published As

Publication number	Publication date
CA2539434A1 (en)	2005-04-07
CA2539434C (en)	2014-03-18
EP2336360A1 (en)	2011-06-22
DK2380985T3 (en)	2014-03-17
EP1842920A1 (en)	2007-10-10
US7858318B2 (en)	2010-12-28
US20110124000A1 (en)	2011-05-26
DE602004025157D1 (de)	2010-03-04
US8097410B2 (en)	2012-01-17
JP5094920B2 (ja)	2012-12-12
EP2380985B1 (en)	2014-01-01
US7687233B2 (en)	2010-03-30
AU2010203318A1 (en)	2010-08-12
ATE455174T1 (de)	2010-01-15
JP2010268803A (ja)	2010-12-02
ES2339710T3 (es)	2010-05-24
DK1842920T3 (da)	2010-05-03
US20070190614A1 (en)	2007-08-16
ES2453895T3 (es)	2014-04-08
US7524665B2 (en)	2009-04-28
PL1842920T5 (pl)	2018-04-30
EP1842920B2 (en)	2017-06-21
US20090215045A1 (en)	2009-08-27
EP2380985A1 (en)	2011-10-26
US20090215061A1 (en)	2009-08-27
JP2007506433A (ja)	2007-03-22
AU2004275828A1 (en)	2005-04-07
PT2380985E (pt)	2014-03-26
JP2012161315A (ja)	2012-08-30
AU2010203318B2 (en)	2012-07-12
EP1670947A2 (en)	2006-06-21
EP1670947A4 (en)	2008-11-05
US20060240440A1 (en)	2006-10-26
HK1093223A1 (en)	2007-02-23
US20070009950A1 (en)	2007-01-11
ES2339710T5 (es)	2017-10-05
WO2005030039A2 (en)	2005-04-07
EP1670947B1 (en)	2015-04-01
DK1842920T4 (da)	2017-08-21
US8426128B2 (en)	2013-04-23
EP1842920B1 (en)	2010-01-13
JP2015180205A (ja)	2015-10-15
WO2005030039A3 (en)	2005-07-21
JP5840539B2 (ja)	2016-01-06
AU2004275828B2 (en)	2010-04-29
US7482141B2 (en)	2009-01-27

Publication	Publication Date	Title
PL1842920T5 (pl)	2018-04-30	Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K
AU2003241311A1 (en)	2003-11-11	Simple catalytic dna biosensors for ions based on color changes
ATE330038T1 (de)	2006-07-15	Nukleinsäure-biosensor
DE602005009702D1 (de)	2008-10-23	Esr1 und gebärmutterhalskrebs
IL172910A0 (en)	2006-06-11	Method for detection of alkylated cytosine in dna
DK1680516T3 (da)	2008-07-21	Ruminddelt autonom mærkning
TW200720441A (en)	2007-06-01	New labelling strategies for the sensitive detection of analytes
WO2007066831A3 (en)	2007-11-08	Method of detecting human papilloma virus by using nucleic acid amplification method and nucleic acid chain-immobilized carrier
DE60228089D1 (de)	2008-09-18	Nukleinsäureamplifikation mit duplexzwischenprodukten
WO2004013305A3 (en)	2004-08-26	Improved compositions for in vitro amplification of nucleic acids
WO2004000995A3 (en)	2004-06-10	Methods, probes, and accessory molecules for detecting single nucleotide polymorphisms
WO2004009843A3 (de)	2004-05-21	Nachweis von mikroorganismen
EP1741793A4 (en)	2008-05-14	HYBRIDIZATION PROCESS
EP1598431A4 (en)	2006-08-16	PROCESS FOR DETECTING CHLAMYDIA TRACHOMATIS AND KIT THEREFOR
WO2005042764A3 (en)	2005-11-03	Primers, methods and kits for amplifying or detecting human leukocyte antigen alleles
CA2451394A1 (en)	2003-02-06	Il-4 receptor sequence variation associated with type 1 diabetes
WO2005024045A3 (en)	2005-09-09	Primers for use in detecting beta-lactamases
WO2003093501A3 (en)	2004-02-05	Ssh based methods for identifying and isolating unique nucleic acid sequences
WO2004029299A3 (de)	2004-07-01	Verfahren zum nachweis und zur differenzierung von bakterien
EP2392667A3 (en)	2012-03-07	Assay for phosphodiesterases
ATE443261T1 (de)	2009-10-15	Scintillation proximity assay
WO2005003388A3 (en)	2005-04-07	Fluorescence assays for nucleic acid polymerase activity
DE60208299D1 (de)	2006-02-02	Detektion von amplifizierten Genprodukten zur Gendetektion und Reagenzkit
WO2003018833A3 (en)	2003-09-12	3-hydroxymethylglutaryl coenzyme a reductase and diagnosis and prognostication of dementia
AU2003285461A8 (en)	2004-05-25	Multienzymatic conductimetric or potentiometric biosensor with unicellular algae, detection method using same